266 related articles for article (PubMed ID: 33163724)
1. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy.
Lafayette RA; Rovin BH; Reich HN; Tumlin JA; Floege J; Barratt J
Kidney Int Rep; 2020 Nov; 5(11):2032-2041. PubMed ID: 33163724
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.
Dudler T; Yaseen S; Cummings WJ
Front Immunol; 2023; 14():1297352. PubMed ID: 38022610
[TBL] [Abstract][Full Text] [Related]
3. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Rambaldi A; Gritti G; Micò MC; Frigeni M; Borleri G; Salvi A; Landi F; Pavoni C; Sonzogni A; Gianatti A; Binda F; Fagiuoli S; Di Marco F; Lorini L; Remuzzi G; Whitaker S; Demopulos G
Immunobiology; 2020 Nov; 225(6):152001. PubMed ID: 32943233
[TBL] [Abstract][Full Text] [Related]
4. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Khaled SK; Claes K; Goh YT; Kwong YL; Leung N; Mendrek W; Nakamura R; Sathar J; Ng E; Nangia N; Whitaker S; Rambaldi A;
J Clin Oncol; 2022 Aug; 40(22):2447-2457. PubMed ID: 35439028
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis.
Selvaskandan H; Kay Cheung C; Dormer J; Wimbury D; Martinez M; Xu G; Barratt J
Nephron; 2020; 144(9):453-458. PubMed ID: 32721954
[TBL] [Abstract][Full Text] [Related]
6. Narsoplimab for severe transplant-associated thrombotic microangiopathy.
Pandrowala A; Ganatra P; Krishnan VP; Sharma AN; Chavan S; Bodhanwala M; Agarwal B; Hiwarkar P
Thromb J; 2023 Mar; 21(1):26. PubMed ID: 36915123
[TBL] [Abstract][Full Text] [Related]
7. Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H-Related Protein-5 (FHR5) Deposition.
Medjeral-Thomas NR; Troldborg A; Constantinou N; Lomax-Browne HJ; Hansen AG; Willicombe M; Pusey CD; Cook HT; Thiel S; Pickering MC
Kidney Int Rep; 2018 Mar; 3(2):426-438. PubMed ID: 29725647
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
Lv J; Liu L; Hao C; Li G; Fu P; Xing G; Zheng H; Chen N; Wang C; Luo P; Xie D; Zuo L; Li R; Mao Y; Dong S; Zhang P; Zheng H; Wang Y; Qin W; Wang W; Li L; Jiao W; Fang J; Zhang H
Kidney Int Rep; 2023 Mar; 8(3):499-506. PubMed ID: 36938094
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.
Castelli M; Micò MC; Grassi A; Algarotti A; Lussana F; Finazzi MC; Rambaldi B; Pavoni C; Rizzuto G; Tebaldi P; Vendemini F; Verna M; Bonanomi S; Biondi A; Balduzzi A; Rambaldi A; Gotti G
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38773280
[TBL] [Abstract][Full Text] [Related]
10. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy.
Endo M; Ohi H; Ohsawa I; Fujita T; Matsushita M; Fujita T
Nephrol Dial Transplant; 1998 Aug; 13(8):1984-90. PubMed ID: 9719152
[TBL] [Abstract][Full Text] [Related]
11. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
12. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of IgA nephropathy with biological agents.
Zhuang Y; Lu H; Li J
Chronic Dis Transl Med; 2024 Mar; 10(1):1-11. PubMed ID: 38450299
[TBL] [Abstract][Full Text] [Related]
14. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
15. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
16. The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?
Poppelaars F; Faria B; Schwaeble W; Daha MR
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682837
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
18. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.
Liu LJ; Lv JC; Shi SF; Chen YQ; Zhang H; Wang HY
Am J Kidney Dis; 2012 Jan; 59(1):67-74. PubMed ID: 22019331
[TBL] [Abstract][Full Text] [Related]
19. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study.
Gong WY; Liu M; Luo D; Liu FN; Yin LH; Li YQ; Zhang J; Peng H
BMC Nephrol; 2019 Apr; 20(1):150. PubMed ID: 31039758
[TBL] [Abstract][Full Text] [Related]
20. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
